Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidance Needed To Explain Scope Of MDR’s Confusing Clinical Investigations Clause

Executive Summary

Article 61(5) of the EU’s Medical Device Regulation gives certain manufacturers an exemption from having to perform clinical investigations by demonstrating equivalence to other companies’ products. But to whom does it apply and who could actually make use of it? Dr. Maria Donawa explains why clarification is urgently needed.

You may also be interested in...



TEAM-NB Highlights Survey Figures Suggesting Massive 2024 Bulge In MDR Applications

Growing evidence demonstrates the one-year delay to the Medical Device Regulation, plus the expansion of the scope of products that could remain on the market beyond the MDR date of application, have simply pushed problems to 2024.

High-Risk Class D IVDs: Some Good News, Some Bad News About IVDR Implementation

The European Commission’s just updated Rolling Implementation Plan for the MDR and IVDR shows delays in key structures for high-risk IVDs. Recent guidance clarifies how and when these products can still proceed to CE marking.

How MDR Delay And Grace Period Expansion Saved Medtech, But Why Another Crisis Looms

Warnings gathered pace around a year ago that EU MDR implementation delays would see hundreds, even thousands, of products removed from market. MedTech Europe’s Oliver Bisazza explains how a disastrous situation was avoided but industry is still in choppy waters.

Topics

UsernamePublicRestriction

Register

MT125805

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel